JERUSALEM, May 14 (Xinhua) -- Israel's Tel Aviv University (TAU) and Neovii, a Swiss-based biopharmaceutical company, announced on Thursday that they have signed an agreement to advance a patent-based COVID-19 vaccine.
The agreement grants Neovii the exclusive right to develop and commercialize a recently patented platform technology conceived by TAU for the rapid discovery of advanced vaccines.
Under the agreement, Neovii will work in close collaboration with a team of scientists from TAU's School of Molecular Cell Biology and Biotechnology to complete the vaccine's development.
According to TAU and Neovii, the first-in-class vaccine is designed to harm the coronavirus' receptor binding motif (RBM), a critical structure of its "spike" protein. Enditem
